Tag: Walking impairment

According to pivotal clinical trials, a significantly greater percentage of people with multiple sclerosis (MS) taking Ampyra experienced a consistent improvement in walking speed compared to those on a placebo. The answer to **Does Ampyra really work?** is therefore a conditional 'yes'—it is effective for a subset of the patient population, but not all patients will experience the same benefits.

Dalfampridine, a medication known commercially as Ampyra, is a potassium channel blocker approved by the FDA in 2010 to improve walking in adults with multiple sclerosis (MS). The query "What is Dalfampridine Mims?" often arises from healthcare professionals and patients consulting the MIMS (Monthly Index of Medical Specialities) database, a common pharmaceutical reference in many countries. This article clarifies the relationship between dalfampridine and the MIMS database, explaining the drug's mechanism of action, clinical use, and safety profile.